TABLE 6.
GMTs and 95% CIs for SBA titers and the percentage of vaccine responders after vaccination with a monovalent and/or hexavalent OMV vaccine
| Strain | Trial I (n = 20)
|
Trial II (n = 20)
|
Trial III (n =20)
|
|||
|---|---|---|---|---|---|---|
| GMT (95% CI) | % of children with 4-fold increase in titer | GMT (95% CI) | % of children with 4-fold increase in titer | GMT (95% CI) | % of children with 4-fold increase in titer | |
| P1.7-2,del1 | 168.9 (105.9-269.3) | 100 | 128.0 (69.2-236.9) | 95 | 21.1 (9.0-49.1) | 68 |
| P1.7-2,del3 | 68.6 (36.8-127.8) | 90 | 52.0 (25.0-108.0) | 80 | 16.6 (7.1-38.5) | 60 |
| P1.7-2,del2 | 5.7 (3.1-10.3) | 30 | 6.7 (3.9-11.5) | 50 | 2.5 (2.2-3.0) | 0 |
| P1.7-11,4 | 19.0 (9.9-36.6) | 80 | 107.6 (56.0-206.8) | 100 | 163.1 (103.5-257.0) | 100 |
| P1.12-1,4 | NDa | ND | ND | ND | 3.2 (2.0-5.2) | 20 |
| P1.7-8,4-1 | 2.8 (1.9-4.1) | 15 | 3.7 (2.0-6.8) | 6 | 5.5 (3.1-9.7) | 40 |
| P1.18,4-1 | ND | ND | ND | ND | 8.0 (4.8-13.2) | 60 |
| P1.21-5,4-3 | ND | ND | ND | ND | 512 | 95 |
| P1.7-2,4 vaccine strain | 13.0 (7.9-21.3) | 100 | 28.8 (16.2-51.4) | 100 | 71.0 (43.7-115.4) | 100 |
a
ND, not done.